VEGFA and hepatocellular carcinoma: A randomized study evaluating atezolizumab (anti-PD-L1 therapy) as monotherapy vs. the combination of atezolizumab + bevacizumab (anti-VEGF therapy; Arm F), as well as single-arm atezolizumab + bevacizumab (Arm A) from a Phase 1b GO30140 study, was conducted in advanced HCC patients and suggested superiority of combination therapy [22].